PharmaCyte Biotech (NASDAQ:PMCB) Trading Down 1.6%

PharmaCyte Biotech, Inc. (NASDAQ:PMCBGet Free Report) shares fell 1.6% during mid-day trading on Tuesday . The stock traded as low as $2.34 and last traded at $2.44. 345,489 shares were traded during mid-day trading, an increase of 1,220% from the average session volume of 26,169 shares. The stock had previously closed at $2.48.

PharmaCyte Biotech Trading Down 1.6 %

The stock has a market capitalization of $20.65 million, a PE ratio of -2.03 and a beta of -0.20. The firm’s fifty day moving average is $2.15 and its 200-day moving average is $2.18.

Institutional Trading of PharmaCyte Biotech

Institutional investors and hedge funds have recently bought and sold shares of the business. CSS LLC IL purchased a new stake in PharmaCyte Biotech during the second quarter worth about $38,000. Sabby Management LLC purchased a new stake in PharmaCyte Biotech during the third quarter worth about $204,000. K2 Principal Fund L.P. increased its stake in PharmaCyte Biotech by 67.6% during the third quarter. K2 Principal Fund L.P. now owns 258,481 shares of the company’s stock worth $543,000 after purchasing an additional 104,249 shares during the period. Equitec Proprietary Markets LLC increased its stake in PharmaCyte Biotech by 34.7% during the third quarter. Equitec Proprietary Markets LLC now owns 82,727 shares of the company’s stock worth $174,000 after purchasing an additional 21,312 shares during the period. Finally, State Street Corp purchased a new stake in PharmaCyte Biotech during the first quarter worth about $86,000. 15.99% of the stock is currently owned by hedge funds and other institutional investors.

About PharmaCyte Biotech

(Get Free Report)

PharmaCyte Biotech, Inc, a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.

Further Reading

Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.